Different from these studies, the HIF2α inhibitor we chose was PT2385, which has been used in a phase II clinical trial for treating renal clear cell carcinoma and has been shown to be safer and more efficacious than other HIF2α inhibitors in humans [46,47]. This evidence concerns the gene EPAS1 and clear cell renal carcinoma.